Mario Aguirre
Family · Brawley, CANPI 1366813065
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,420, 3.6 times the $399 reported in 2021. Among family clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $27.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$516
- Novo Nordisk$461
- Lilly USA, LLC$383
- Corcept Therapeutics$219
- AstraZeneca$217
- Biohaven Pharmaceutical Holding Company Ltd.$194
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,291100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 18 | $516 |
| Novo Nordisk | 10 | $461 |
| Lilly USA, LLC | 5 | $383 |
| Corcept Therapeutics | 6 | $219 |
| AstraZeneca | 6 | $217 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $194 |
| Amgen | 19 | $168 |
| GSK | 6 | $163 |
| Biogen | 6 | $138 |
| Silk Road Medical, Inc. | 1 | $130 |
| Bayer | 1 | $127 |
| Cequr Corporation | 1 | $102 |
| Acadia Pharmaceuticals Inc | 4 | $74 |
| Shield Therapeutics Inc | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Pfizer | 2 | $36 |
| Averitas Pharma Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| EMD Serono, Inc. | 1 | $27 |
| Vision Quest Industries Inc. | 2 | $26 |
| Seqirus USA Inc | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $20 |
| Medtronic | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$259
- AIRSUPRA$133
- ENROUTE Transcarotid Neuroprotection System$130
- ENROUTE Transcarotid Stent$130
- Kerendia$127
- KISUNLA$125
- Wegovy$125
- ZEPBOUND$125
- Ozempic$124
- Korlym$115
- MOUNJARO$105
- CeQur Simplicity$102
How this compares
$3,291 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 165 | $152,021 |
| RybelsusSemaglutide | 82 | $94,472 |
| JardianceEmpagliflozin | 45 | $45,721 |
| FarxigaDapagliflozin Propanediol | 58 | $42,223 |
| EliquisApixaban | 55 | $36,759 |
| LinzessLinaclotide | 50 | $34,437 |
| XareltoRivaroxaban | 25 | $26,763 |
| EntrestoSacubitril/Valsartan | 24 | $24,675 |
| JanuviaSitagliptin Phosphate | 24 | $20,429 |
| TrulicityDulaglutide | 19 | $19,344 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $14,157 |
| MounjaroTirzepatide | 14 | $13,548 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $10,629 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,439 |
| Diclofenac Sodium | 73 | $7,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $461 | $246,493247 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $217 | $55,32783 claims |
| PfizerEliquis | $36 | $36,75955 claims |
| AbbVieLinzess | $516 | $34,43750 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $383 | $32,89233 claims |
| GSKTrelegy Ellipta | $163 | $9,43912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Brawley
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.